Diasome Pharmaceuticals raises at least $20M for diabetes drug trials


If the drug succeeds in clinical trials, Diasome likely would license its technology to or be acquired by a "top global pharmaceutical company," the company's commercial development leader said.

Previous Health Care Hero: Infectious disease expert has followed passion for 40 years
Next State picks North Florida farmer for pot license

No Comment

Leave a reply

Your email address will not be published.